Analyst Price Targets — PETS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 12, 2024 8:51 am | Ryan Meyers | Lake Street | $7.00 | $4.14 | TheFly | PetMed Express price target lowered to $7 from $9 at Lake Street |
| June 12, 2024 8:44 am | Ryan Meyers | Loop Capital Markets | $7.00 | $4.13 | StreetInsider | PetMed Express (PETS) PT Lowered to $7 at Lake Street Capital Markets |
| July 26, 2022 8:03 am | — | Morgan Stanley | $19.00 | $20.25 | Benzinga | Morgan Stanley Maintains Underweight on PetMed Express, Lowers Price Target to $19 |
| May 10, 2022 9:09 am | — | Morgan Stanley | $20.00 | $22.22 | Benzinga | Morgan Stanley Maintains Underweight on PetMed Express, Lowers Price Target to $20 |
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for PETS

DELRAY BEACH, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., doing business as PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that its new online pet pharmacy offering with Rural King is now available, giving Rural King customers convenient access to trusted pet medications, prescription food, preventatives and pet health products through a new co-branded online pharmacy…

DELRAY BEACH, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (“PetMeds” or the “Company”) (Nasdaq: PETS) today confirmed that its Board of Directors (the “Board”) has received an unsolicited, non-binding, and conditional proposal from SilverCape Investments Limited (“SilverCape”) to acquire all outstanding shares of the Company's common stock for $3.00 per share in cash, following SilverCape's prior…

Unaccountable Board Led by Chair & Interim CEO Leslie C.G. Campbell Continues to Preside Over Stunning Destruction of Stockholder Value

PetMed says FY26 reset is working. Its Q4 sales top estimates, margins improve, and it stays independent after $4-$4.25 offers and touts B2B expansion.

PetMed (PETS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.56 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PETS.
U.S. House Trading
No House trades found for PETS.
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
